2.43
price up icon3.85%   0.09
pre-market  Pre-mercato:  2.51   0.08   +3.29%
loading
Precedente Chiudi:
$2.34
Aprire:
$2.34
Volume 24 ore:
2.76M
Relative Volume:
0.77
Capitalizzazione di mercato:
$682.59M
Reddito:
$12.87M
Utile/perdita netta:
$-114.34M
Rapporto P/E:
-2.8105
EPS:
-0.8646
Flusso di cassa netto:
$-79.23M
1 W Prestazione:
-0.41%
1M Prestazione:
-12.75%
6M Prestazione:
+31.35%
1 anno Prestazione:
+12.50%
Intervallo 1D:
Value
$2.34
$2.505
Intervallo di 1 settimana:
Value
$2.25
$2.505
Portata 52W:
Value
$1.05
$3.31

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Nome
Taysha Gene Therapies Inc
Name
Telefono
(214) 612-0000
Name
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Name
Dipendente
73
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
TSHA's Discussions on Twitter

Confronta TSHA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
2.43 682.59M 12.87M -114.34M -79.23M -0.8646
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-06-27 Iniziato BMO Capital Markets Outperform
2024-04-09 Iniziato Piper Sandler Overweight
2023-02-01 Downgrade Jefferies Buy → Hold
2023-01-27 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-11-09 Downgrade Goldman Buy → Neutral
2022-03-09 Iniziato Robert W. Baird Outperform
2022-03-01 Iniziato Wells Fargo Overweight
2022-02-18 Iniziato SMBC Nikko Outperform
2021-12-16 Iniziato Guggenheim Buy
2021-07-16 Iniziato Needham Buy
2021-06-24 Iniziato Truist Buy
2021-06-15 Iniziato BTIG Research Buy
2021-06-09 Iniziato Wedbush Outperform
2021-06-08 Iniziato JMP Securities Mkt Outperform
2021-05-19 Iniziato Cantor Fitzgerald Overweight
2021-05-11 Ripresa Jefferies Buy
2021-02-24 Iniziato William Blair Outperform
2021-01-05 Iniziato Oppenheimer Outperform
2020-10-19 Iniziato Chardan Capital Markets Buy
2020-10-19 Iniziato Goldman Buy
2020-10-19 Iniziato Jefferies Buy
2020-10-19 Iniziato Morgan Stanley Overweight
Mostra tutto

Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie

pulisher
Jun 14, 2025

Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome therapy boosts stock outlook - Investing.com Australia

Jun 14, 2025
pulisher
Jun 13, 2025

Taysha Gene Therapies price target maintained at $13 by Cantor Fitzgerald - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

Taysha gene therapies stock rating reiterated by Cantor Fitzgerald - Investing.com Canada

Jun 12, 2025
pulisher
Jun 11, 2025

Taysha Gene Therapies (TSHA) Price Target Raised Amid High Trial Success Confidence | TSHA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $13 From $7, Maintains Overweight Rating - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Needham Reiterates Buy Rating for Taysha Gene Therapies (TSHA) | - GuruFocus

Jun 10, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Signify Bio’s $15M round advances in situ protein therapeutics - BioWorld MedTech

Jun 06, 2025
pulisher
Jun 06, 2025

Kalkine: Taysha Gene Therapies Grants Equity Awards to New Joiners – A Closer Look at FTSE 350 Companies' Global Peers - Kalkine Media

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies (TSHA) Grants Stock Options to New Employees | TSHA Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Gene Therapy Leader Taysha Awards Massive 401K Share Options Package to Key New Executives - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus - Value The Markets

Jun 05, 2025
pulisher
Jun 04, 2025

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by ProShare Advisors LLC - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Acquires New Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Jane Street Group LLC Acquires 62,003 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Given New $11.00 Price Target at Canaccord Genuity Group - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Taysha reports progress in Rett syndrome gene therapy trials By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data By Stocktwits - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

taysha gene therapies increases authorized shares to 700 million By Investing.com - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies (TSHA) Advances TSHA-102 Program for Rett - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details for Oral Presentations a - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha reports progress in Rett syndrome gene therapy trials - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program - The Manila Times

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details For Oral Presentations - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program | TSHA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details for Oral - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Needham Lifts Taysha Gene Therapies (TSHA) PT to $8, Cites Positive Clinical Data - Insider Monkey

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies (TSHA) Target Price Raised by Canaccord Ge - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies (TSHA) Price Target Raised by Canaccord | - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

taysha gene therapies increases authorized shares to 700 million - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Approves Share Increase Amendment - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies (TSHA) Price Target Raised by Canaccord | TSHA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Positive Outlook for Taysha Gene Therapies: Buy Rating on Promising TSHA-102 Advancements - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Taysha Gene Therapies (TSHA) Updates Clinical Progress in Rett S - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Where Taysha Gene Therapies Stands With Analysts - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Needham Adjusts Taysha Gene Therapies Price Target to $8 From $6, Maintains Buy Rating - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Taysha Gene Therapies (TSHA) Sees Increased Price Target by Needham | TSHA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Needham Increases Price Target for Taysha Gene Therapies (TSHA) to $8 | TSHA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data - MSN

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stake Lessened by Deutsche Bank AG - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Bank of America Corp DE Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 01, 2025

Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):